Hepatic steatosis and insulin resistance: Does etiology make a difference?

被引:34
作者
Lonardo, A
Lombardini, S
Scaglioni, F
Carulli, L
Ricchi, M
Ganazzi, D
Adinolfi, LE
Ruggiero, G
Carulli, N
Loria, P
机构
[1] Nuovo Osped Civile Estense, Unita Operat Med Interna & Gastroenterol, I-41100 Modena, Italy
[2] Univ Modena & Reggio Emilia, Dipartimento Med Interna, Modena, Italy
[3] Univ Naples Federico II, Cattedra Med Interna, Naples, Italy
关键词
familial heterozygous hypobetalipoproteinemia; insulin resistance; HOMA-IR; HCV; liver biopsy; NAFLD; steatosis; ultrasonography;
D O I
10.1016/j.jhep.2005.06.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: To ascertain whether the etiology of hepatic steatosis modulates insulin resistance (IR) and to determine the predictors of IR. Methods: We studied IR through HOMA IR in 146 subjects, 99 of whom had ultrasonographic and/or histologic steatosis. Twenty-two had familial heterozygous hypobetalipoproteinemia (FHBL), 48 had non-alcoholic fatty liver disease (NAFLD), 34 HCV infection (17 with HCV1b, 17 with HCV3a) and 42 were healthy controls without steatosis. Results: Steatosis was present in 77.3% of FHBL and, by enrolment criteria, in all NAFLD and HCV cases. Overall HOMA-IR correlated with BMI and GGT (P < 0.01). FHBL and healthy groups had similar HOMA-IR and GGT values, whereas higher levels were observed in HCV and NAFLD. HCV3a and FHBL patients were hypolipidemic. HONIA-IR was similar in FHBL patients and controls and lower than in HCV and NAFLD. FHBL patients had a high extent of steatosis, similar to that observed in HCV3a, but lower grading and staging than NAFLD and HCV. At multivariate analysis, steatosis and GGT predicted HOMA-IR. Conclusions: Data suggest that not all hepatic fat associates with IR. FHBL patients, for some aspects, resemble HCV3a infection, possibly suggesting a shared steatogenic mechanism. Among steatotic patients serum GGT levels is the independent predictor of IR. (c) 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:190 / 196
页数:7
相关论文
共 46 条
[1]   Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity [J].
Adinolfi, LE ;
Gambardella, M ;
Andreana, A ;
Tripodi, MF ;
Utili, R ;
Ruggiero, G .
HEPATOLOGY, 2001, 33 (06) :1358-1364
[2]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[3]  
Balkau B, 1999, DIABETIC MED, V16, P442
[4]   EPIDEMIOLOGY OF GALLSTONE DISEASE IN ITALY - PREVALENCE DATA OF THE MULTICENTER ITALIAN STUDY ON CHOLELITHIASIS (MICOL) [J].
BARBARA, L ;
CAPOCACCIA, L ;
MENOTTI, A ;
MUNTONI, S ;
RICCI, G .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 141 (02) :158-165
[5]   Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions [J].
Brunt, EM ;
Janney, CG ;
Di Bisceglie, AM ;
Neuschwander-Tetri, BA ;
Bacon, BR .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (09) :2467-2474
[6]   Relative contribution of iron burden, HFE mutation and insulin resistance to fibrosis in nonalcoholic fatty liver [J].
Bugianesi, E ;
Manzini, P ;
D'Antico, S ;
Vanni, E ;
Longo, F ;
Leone, N ;
Massarenti, P ;
Piga, A ;
Marchesini, G ;
Rizzetto, M .
HEPATOLOGY, 2004, 39 (01) :179-187
[7]   NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome [J].
Chitturi, S ;
Abeygunasekera, S ;
Farrell, GC ;
Holmes-Walker, J ;
Hui, JM ;
Fung, C ;
Karim, R ;
Lin, R ;
Samarasinghe, D ;
Liddle, C ;
Weltman, M ;
George, J .
HEPATOLOGY, 2002, 35 (02) :373-379
[8]   The metabolic syndrome [J].
Eckel, RH ;
Grundy, SM ;
Zimmet, PZ .
LANCET, 2005, 365 (9468) :1415-1428
[9]  
*EXP COMM DIAGN CL, 2002, DIABETES CARE, pS1
[10]   Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report [J].
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, R ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Cleeman, JI ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ ;
Keller, SA ;
Jehle, AJ .
CIRCULATION, 2002, 106 (25) :3143-3421